Cidara Therapeutics Announces FDA Acceptance for Priority Review of New Drug Application for Rezafungin for the Treatment of Candidemia and Invasive Candidiasis

Assigned PDUFA target action date of March 22, 2023 SAN DIEGO, Sept. 20, 2022— Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to improve the standard of care for patients...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news